The use of cyclosporin A (CyA) with a protocol designed to avoid the effects of nephrotoxicity resulted in a oneyear survival of 86% in recipients of renal allografts from unmatched cadaveric donors. The drug also controlled rejection of liver and pancreatic allografts. It was possible to change patients initially treated with CyA to azathioprine and corticosteroids and vice versa, thus enlarging the potential value of CyA in organ allografting. Of 34 recipients of renal allografts, 29 were currently receiving only CyA as immunosuppressive treatment. Twelve patients never required any adjuvant steroid treatment.
Introduction
In a pilot study of cyclosporin A (CyA) in organ transplantation we found the agent to be an extremely powerful immunosuppressant which may be effective without corticosteroids in renal, pancreatic, and hepatic allografting.1-3 CyA given to 15 patients with oliguria, however, further impaired renal function, so that additional corticosteroids and "cytimun" (a cyclophosphamide analogue) were given in the mistaken belief that this was a manifestation of rejection, though histological changes did not indicate severe immune reactions. The result was excessive immunosuppression, a high incidence of bacterial, viral, and fungal infection, and the development of three lymphomas. When CyA dosage was reduced below 3 mg/kg in two patients4 severe allograft rejection developed, rapidly controlled by stopping CyA and substituting azathioprine and prednisolone.
We therefore developed a protocol in which CyA was given only to patients with primary functioning kidneys. Administration of fluid and diuretics during operation lowered the incidence of primary oliguria and nephrotoxicity. The use of additional corticosteroids was limited, and if rejection was not quickly controlled CyA was stopped and immunosuppression continued with azathioprine and prednisolone. We also changed patients treated with azathioprine and corticosteroids to CyA in order to alleviate the side effects of corticosteroids.
We report our Conversion: SI to traditional units-Bilirubin: 1 ,imol/1 006 mg/100 ml. Urea: 1 mmol/1 6 mg/100 ml. Creatinine: 1 smol/I 001 mg/100 ml. Glucose: 1 mmol/l 18 mg/100 ml.
Discussion
With this protocol the results obtained with CyA in patients given cadaveric renal allografts were very much better than we had obtained before. Though selected for primary function (but not immunologically), these patients (one-third of whom were over 50) have an 86% predicted graft survival at one year, which is unusual. They included five patients in whom CyA did not control rejection and who were changed satisfactorily to azathioprine and corticosteroids. Starzl et al suggested that corticosteroids should be used routinely in addition to CyA.5 Since three-quarters of our patients with functioning renal allografts were receiving CyA only and nearly a third had never been treated with corticosteroids, we think that patients should be given the chance to avoid the latter drugs. Early experience with continuous administration of corticosteroids with CyA2 was associated with a high incidence of infectious complications and lymphomas. With the new protocol there were no new cases of lymphoma, and probably the development of such tumours is not specifically related to CyA but to excessive and inappropriate immunosuppression.
Nephrotoxicity has been the most serious complication of CyA. Other Transplantation of the pancreas has been undertaken because of the powerful immunosuppressive effect of CyA, which can in some cases control rejection without the need for corticosteroids. Attempts to prevent exocrine secretion by injecting latex into the pancreatic duct6 7 have not always been successful, and infection is likely to be aggravated because latex is a foreign body. We propose in future to inject the ducts with Ethibloc, a polymerised amino-acid, which is broken down in the body. 8 The future of segmental pancreatic allografting depends on whether control of diabetes can prevent progression of microangiopathy and therefore deterioration of vision and renal function. It This may have been due to different mechanisms of action or to variation in absorption or metabolism of CyA in different patients. Patients experiencing side effects with corticosteroids have responded well to CyA. Patients receiving CyA should not be given prolonged courses of corticosteroids or other immunosuppressive agents because of the danger of excessive damage to the immune system, with the attendant risks of infection and lymphoma induction. Thus we find that patients treated with CyA alone are capable of producing a more vigorous humoral response, as assessed by immunoglobulin concentrations, than are those treated with CyA and corticosteroids or conventional immunosuppressive agents."
The ease with which patients may be changed to and from CyA provides a valuable alternative immunosuppressive tool. As maintenance treatment CyA is usually preferable, since corticosteroids can be avoided. Serum creatinine concentrations, however, are higher (208 ,umol/l (2-4 mg/100 ml) at six months) than with conventional drugs (114 ,umol/l (1-3 mg/100 ml) at six months). When patients are changed to azathioprine and prednisolone, serum creatinine concentrations usually fall rapidly, but such changes have been necessitated by poor control of rejection, and improvement in renal function may be due to recovery from rejection as well as to stopping the nephrotoxic CyA. Change to CyA in the absence of rejection is usually followed by a rise in serum creatinine concentrations, which tend to peak and then fall to remain moderately raised.
Our results are encouraging, and a randomised multicentre trial is now planned to compare CyA with conventional azathioprine and corticosteroids in recipients of cadaveric renal allografts.
